vs

Side-by-side financial comparison of AURORA CANNABIS INC (ACB) and Bioceres Crop Solutions Corp. (BIOX). Click either name above to swap in a different company.

AURORA CANNABIS INC is the larger business by last-quarter revenue ($81.6M vs $77.6M, roughly 1.1× Bioceres Crop Solutions Corp.). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -756.4%, a 746.8% gap on every dollar of revenue.

Aurora Cannabis Inc. is a Canadian licensed cannabis producer, headquartered in Edmonton. It trades on the Toronto Stock Exchange and Nasdaq as ACB. As of September 2018, Aurora Cannabis had eight licensed production facilities, five sales licences, and operations in 25 countries. It had a funded capacity of over 625,000 kilograms of cannabis production per annum with the bulk of capacity based in Canada and a growing presence in international markets, particularly Denmark and Latin America. ...

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

ACB vs BIOX — Head-to-Head

Bigger by revenue
ACB
ACB
1.1× larger
ACB
$81.6M
$77.6M
BIOX
Higher net margin
BIOX
BIOX
746.8% more per $
BIOX
-9.6%
-756.4%
ACB

Income Statement — Q1 FY2024 vs Q1 FY2026

Metric
ACB
ACB
BIOX
BIOX
Revenue
$81.6M
$77.6M
Net Profit
$-617.0M
$-7.4M
Gross Margin
8.7%
46.8%
Operating Margin
-73.7%
9.3%
Net Margin
-756.4%
-9.6%
Revenue YoY
-16.8%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACB
ACB
BIOX
BIOX
Q3 25
$77.6M
Q1 25
$60.6M
Q4 24
$98.8M
Q3 24
$93.3M
Q1 24
$84.0M
Q4 23
$140.2M
Q3 23
$116.6M
Q2 23
$81.6M
Net Profit
ACB
ACB
BIOX
BIOX
Q3 25
$-7.4M
Q1 25
$-1.6M
Q4 24
$605.2K
Q3 24
$-6.2M
Q1 24
$9.8M
Q4 23
$1.2M
Q3 23
$-2.7M
Q2 23
$-617.0M
Gross Margin
ACB
ACB
BIOX
BIOX
Q3 25
46.8%
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q1 24
50.8%
Q4 23
36.7%
Q3 23
38.6%
Q2 23
8.7%
Operating Margin
ACB
ACB
BIOX
BIOX
Q3 25
9.3%
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
Q1 24
15.7%
Q4 23
12.0%
Q3 23
4.5%
Q2 23
-73.7%
Net Margin
ACB
ACB
BIOX
BIOX
Q3 25
-9.6%
Q1 25
-2.6%
Q4 24
0.6%
Q3 24
-6.6%
Q1 24
11.6%
Q4 23
0.9%
Q3 23
-2.3%
Q2 23
-756.4%
EPS (diluted)
ACB
ACB
BIOX
BIOX
Q3 25
$-0.12
Q1 25
$-0.02
Q4 24
$0.00
Q3 24
$-0.10
Q1 24
$0.14
Q4 23
$0.00
Q3 23
$-0.07
Q2 23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACB
ACB
BIOX
BIOX
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
Total Assets
$734.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACB
ACB
BIOX
BIOX
Q3 25
$15.5M
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q1 24
$16.4M
Q4 23
$24.4M
Q3 23
$28.4M
Q2 23
Stockholders' Equity
ACB
ACB
BIOX
BIOX
Q3 25
$288.3M
Q1 25
$345.0M
Q4 24
$346.3M
Q3 24
$346.0M
Q1 24
$348.5M
Q4 23
$335.3M
Q3 23
$332.6M
Q2 23
Total Assets
ACB
ACB
BIOX
BIOX
Q3 25
$734.9M
Q1 25
$798.2M
Q4 24
$835.2M
Q3 24
$827.3M
Q1 24
$836.1M
Q4 23
$819.5M
Q3 23
$819.7M
Q2 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACB
ACB
BIOX
BIOX
Operating Cash FlowLast quarter
$-4.3M
$14.4M
Free Cash FlowOCF − Capex
$-8.6M
FCF MarginFCF / Revenue
-10.6%
Capex IntensityCapex / Revenue
5.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACB
ACB
BIOX
BIOX
Q3 25
$14.4M
Q1 25
$23.3M
Q4 24
$-5.4M
Q3 24
$5.2M
Q1 24
$-17.4M
Q4 23
$21.1M
Q3 23
$14.7M
Q2 23
$-4.3M
Free Cash Flow
ACB
ACB
BIOX
BIOX
Q3 25
Q1 25
Q4 24
Q3 24
Q1 24
Q4 23
Q3 23
Q2 23
$-8.6M
FCF Margin
ACB
ACB
BIOX
BIOX
Q3 25
Q1 25
Q4 24
Q3 24
Q1 24
Q4 23
Q3 23
Q2 23
-10.6%
Capex Intensity
ACB
ACB
BIOX
BIOX
Q3 25
Q1 25
Q4 24
Q3 24
Q1 24
Q4 23
Q3 23
Q2 23
5.3%
Cash Conversion
ACB
ACB
BIOX
BIOX
Q3 25
Q1 25
Q4 24
-8.85×
Q3 24
Q1 24
-1.78×
Q4 23
17.05×
Q3 23
Q2 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons